One page, thousands of outlets. See who else covered it.
Summit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated dataset that may spell trouble ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
[Vanguard] ...Experts warn: Ignorance, poor awareness fueling discrimination, delay diagnosis
MALAGA has banned swimming at six beaches across the city after water samples revealed dangerous levels of E. coli bacteria.
UnitedHealth faces an investigation over tax payments, and we examine why PE deals for doctor groups are slowing.
GEN asked leaders in biomanufacturing: What technologies do you use to carry out effective impurity removal at specific points throughout upstream and downstream processing to ensure product quality…
AstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster…
The U.S. Federal Trade Commission has opened an antitrust investigation into Epic and is looking into its data-sharing practices, Reuters reported on Friday.